Valomaciclovir Polymorph A Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Valomaciclovir, a potent anti-herpes agent, has faced challenges in developing stable crystalline forms due to its guanine moiety, amino acid ester, and long chain fatty acid ester components, leading to poor flowability and agglomeration issues, which have hindered its clinical formulation, especially for elderly patients.
Innovation Solution
The development of stable crystalline forms of valomaciclovir, specifically Polymorph A, through a reproducible process involving dissolution in a lower alkanol solvent or mixed solvents, followed by controlled cooling and crystallization, to produce a thermodynamically stable and highly crystalline form suitable for pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If valomaciclovir is synthesized using prior art synthetic routes, then the chemical compound is produced, but the material exhibits poor flowability and agglomeration due to amorphous or partially ordered structures
Solution Approach 1:
The patent applies parameter changes by modifying the crystallization conditions including solvent selection (lower alkanols like n-propanol, n-butanol), temperature profiles (cooling rates from 0.1 to 10°C per hour), and pH control during crystallization. These parameter changes transform the material from amorphous or partially ordered structures to well-defined crystalline forms (Polymorph A, B, C) with improved flowability and handling characteristics while maintaining chemical stability
Solution Approach 2:
The patent utilizes phase transitions by controlling the crystallization process from solution phase to solid crystalline phase. By carefully controlling cooling rates and solvent evaporation, the patent achieves controlled phase transition that produces stable crystalline polymorphs with defined molecular packing arrangements, eliminating the amorphous nature of previously synthesized material
2Ease of operation
If liquid suspensions are used to avoid handling difficulties, then processing is simplified, but administration becomes difficult especially for elderly patients
Solution Approach 1:
The patent changes the physical state parameter from liquid suspension to solid crystalline form. This parameter change enables the drug to be formulated as tablets or capsules that are easy to administer to elderly patients while maintaining good flowability and handling properties through controlled crystallization processes
3Ease of manufacture
If valomaciclovir is synthesized without controlled crystallization, then the synthesis process is simpler, but the product lacks reproducibility and stability
Solution Approach 1:
The patent applies preliminary action by pre-establishing optimized crystallization protocols including specific solvent selections (lower alkanols), predetermined cooling rates (0.1 to 10°C per hour), and controlled pH conditions. These preliminary established parameters ensure that when the crystallization step is performed, it reliably produces stable polymorphs with consistent properties, making the overall manufacturing process reproducible while remaining practical
Solution Approach 2:
The patent implements feedback control by monitoring crystallization parameters such as temperature, solvent composition, and pH during the process. By measuring these parameters and adjusting them according to established relationships, the process ensures consistent production of stable crystalline forms with defined polymorphic structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a stable, reproducible, and highly crystalline form of valomaciclovir (Polymorph A) that improves handling and processing, enabling effective oral administration and enhanced therapeutic efficacy against viral infections such as varicella zoster virus and herpes simplex viruses.
Implementation Method 1
dissolving valomaciclovir in a lower alkanol solvent or a mixed solvent of lower alkanols by heating to an appropriate internal temperature
Implementation Method 2
cooling with stirring to effect substantial crystallization of valomaciclovir
Implementation Method 3
cooling with stirring to effect substantial crystallization of valomaciclovir, and collecting the crystalline product
Data Source
AI summary
The present invention relates to crystalline forms of valomaciclovir, processes for preparing crystalline forms of valomaciclovir, pharmaceutical compositions thereof and methods of using thereof.